BRAF and metastatic melanoma: Lifileucel, an autologous tumor-infiltrating lymphocyte (TIL) therapy, received accelerated FDA approval in 2024 for the treatment of patients with unresectable or metastatic melanoma who had previously progressed on PD-1 inhibitors and, if applicable, BRAF-targeted therapies [39].